Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...

Frozen’s Josh Gad shared insight into his weight loss journey after losing 40 pounds with the help of medication.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...